GLP-1 Drugs and Mental Health: What the Evidence Actually Shows

In January 2025, the FDA completed the largest investigation ever conducted into GLP-1 receptor agonists and psychiatric risk. After reviewing 91 placebo-controlled trials involving 107,910 participants, the agency found no increased risk of suicidal ideation, depression, anxiety, or other psychiatric adverse events. The FDA then took the unusual step of requesting that manufacturers remove the suicidal ideation warning from GLP-1 drug labels entirely.

That alone would be reassuring. But the story does not end there. Post hoc analyses of the major weight loss trials — STEP (semaglutide) and SURMOUNT (tirzepatide) — have found that these drugs may actually improve depressive symptoms compared to placebo. And the neuroscience is beginning to explain why: GLP-1 receptors are expressed throughout brain regions that regulate mood, and their activation appears to reduce neuroinflammation, upregulate BDNF, and improve synaptic plasticity.

This page covers what the clinical evidence shows, the biological mechanisms behind it, where the pharmacovigilance data complicates the picture, and what retatrutide's triple-agonist mechanism might mean for mental health outcomes.

Nothing on this page constitutes medical advice. Retatrutide is an investigational drug that has not been approved by the FDA. If you are experiencing depression or suicidal thoughts, contact your healthcare provider or call the 988 Suicide and Crisis Lifeline.

The FDA Investigation: Timeline and Outcome

The FDA's review of GLP-1 drugs and psychiatric safety unfolded over approximately 18 months. Understanding the timeline matters because it shows how seriously the agency investigated the concern — and how definitive the conclusion was.

The meta-analysis included 60,338 patients treated with a GLP-1 RA and 47,572 treated with placebo. The results showed no increased risk for suicidal ideation and behavior, and no increased risk for other psychiatric adverse events including anxiety, depression, irritability, or psychosis.

The FDA's decision to request label removal — rather than simply stating no increased risk — reflects the strength of the evidence. Regulatory agencies rarely request the removal of safety warnings once they have been added.

Clinical Trial Data: Depression Scores Actually Improved

Two major post hoc analyses have now examined depression outcomes using the PHQ-9 (Patient Health Questionnaire-9), a validated depression screening tool, in the largest GLP-1 weight loss trials. Both found the same thing: patients on the active drug had slightly but statistically significantly better depression scores than those on placebo.

Semaglutide: STEP 1, 2, 3, and 5

Wadden et al. published a post hoc analysis in JAMA Internal Medicine (2024) examining 3,377 participants across the STEP 1, 2, and 3 trials and 304 participants in STEP 5. Key findings:

• PHQ-9 scores at week 68: 2.0 (semaglutide) vs 2.4 (placebo)
• Estimated treatment difference: -0.56 (95% CI: -0.81 to -0.32; p < 0.001)
• Semaglutide-treated patients were less likely to shift to a more severe depression category (OR 0.63; 95% CI: 0.50-0.79; p < 0.001)
• Suicidal ideation/behavior reported by 1% or fewer of participants, with no difference between groups

Tirzepatide: SURMOUNT Trials

Wadden et al. published a parallel analysis in Obesity (2026) examining 4,056 adults across three SURMOUNT trials over 72 weeks:

• PHQ-9 scores at week 72: 1.9 (tirzepatide) vs 2.4 (placebo)
• Tirzepatide showed a 0.6-point greater reduction than placebo (p < 0.001)
• Participants on tirzepatide were less likely to shift to more severe depression categories (18.2% vs 24.3%; p < 0.001)
• Suicidal ideation reported by 0.6% of the tirzepatide group, with most events deemed low risk

The treatment differences are small in absolute terms — these are not antidepressant-level effects. But the direction is consistent and statistically significant: GLP-1 drugs do not worsen depression and may modestly improve it.

How GLP-1 Drugs Affect the Brain

The clinical findings are supported by a growing body of neuroscience research explaining how GLP-1 receptor activation influences mood-related brain circuits. GLP-1 receptors are not just found in the pancreas and gut — they are expressed throughout the central nervous system.

Brain Regions With GLP-1 Receptors

GLP-1 receptors are expressed in several brain regions directly involved in mood regulation, reward processing, and cognition:

• Hippocampus — memory formation, neurogenesis, and a key region in depression pathophysiology
• Amygdala — emotional processing, fear, and anxiety regulation
• Ventral tegmental area (VTA) — dopamine-driven reward signaling
• Hypothalamus — stress response (HPA axis) regulation
• Prefrontal cortex — executive function and emotional regulation

GLP-1 and its analogs can cross the blood-brain barrier, allowing peripherally administered drugs like semaglutide and retatrutide to directly affect central nervous system function.

Mechanisms Linking GLP-1 to Mood

In preclinical studies, 15 out of 18 studies (83%) reported significant antidepressant-like effects from GLP-1 receptor agonists, associated with enhanced neuroplasticity, reduced neuroinflammation, and neurotransmitter alterations.

The GIP Receptor: A Cognitive Advantage for Dual and Triple Agonists

This is where the story becomes particularly relevant to tirzepatide and retatrutide. Both drugs activate the GIP (glucose-dependent insulinotropic polypeptide) receptor in addition to GLP-1 — and the GIP receptor has its own distinct role in brain function.

What GIPR Knockout Studies Show

Research in GIPR knockout mice has demonstrated clear cognitive deficits:

• Impaired recognition and spatial learning — knockout mice failed to discriminate between novel and familiar objects in recognition tasks
• Impaired spatial memory — knockout mice struggled to locate escape platforms in Morris water maze trials compared to wild-type controls
• Reduced synaptic plasticity — genetic deletion of GIPR impaired long-term potentiation (LTP) in hippocampal area CA1
• Reduced neurogenesis — GIPR knockout mice had fewer BrdU-positive cells in the dentate gyrus, indicating compromised cell proliferation

Importantly, peripheral GIP antagonism did not produce these effects, suggesting that GIP's cognitive benefits are mediated through local neurocrine pathways in the brain rather than through peripheral metabolic signaling.

What This Means for Retatrutide

Retatrutide activates all three receptors — GLP-1, GIP, and glucagon. The GIP component is shared with tirzepatide (Mounjaro/Zepbound), which has already shown favorable depression outcomes in the SURMOUNT post hoc analysis and no depression signal in pharmacovigilance databases. The potential cognitive and neuroprotective benefits of GIP receptor activation are not available from GLP-1-only drugs like semaglutide.

Whether retatrutide's triple-agonist mechanism produces additive or synergistic effects on brain function remains to be studied. But the preclinical evidence for GIP receptor involvement in cognition and neuroplasticity provides a biological rationale for why dual and triple agonists might have a distinct mental health profile compared to GLP-1 monoagonists.

Pharmacovigilance Data: A More Complicated Picture

While clinical trial data and the FDA meta-analysis are reassuring, pharmacovigilance databases — which collect real-world adverse event reports — tell a more nuanced story.

FAERS Analysis Findings

Disproportionality analyses of the FDA Adverse Event Reporting System (FAERS) have found:

• Semaglutide: Significant signal for depression (ROR 1.87; 95% CI: 1.60-2.20) and suicide/self-injury events (ROR 1.73; 95% CI: 1.46-2.04) in one analysis. A separate analysis found an ROR of 1.26 (95% CI: 1.15-1.37) for depressive disorders.
• Tirzepatide: No significant disproportionate reporting signal for depression or suicidality
• Liraglutide: No significant disproportionate reporting signal

How to Interpret This

FAERS data has important limitations. Reporting odds ratios reflect how often an event is reported relative to other drugs in the database — they do not establish causation. Several factors could explain the semaglutide-specific signal:

• Market exposure: Semaglutide (Ozempic/Wegovy) has far greater market penetration than tirzepatide, leading to more reports overall
• Reporting bias: Media coverage of GLP-1 drugs and mental health may have increased reporting specifically for semaglutide
• Population differences: The patient populations using each drug may differ in baseline psychiatric risk
• Stimulated reporting: The FDA's investigation itself may have prompted more adverse event reports

The FDA's own meta-analysis of controlled clinical trials — which eliminates these biases — found no increased risk. The FAERS signal for semaglutide warrants ongoing monitoring, but it should be interpreted in the context of the much stronger clinical trial evidence showing no increased risk and potential benefit.

Retatrutide: What the TRIUMPH Program Will Tell Us

Retatrutide is currently in Phase 3 clinical trials through the TRIUMPH program, which includes over 5,800 participants across four studies. While specific psychiatric outcome data from TRIUMPH has not yet been published, several factors are relevant:

Systematic Psychiatric Monitoring

Given the regulatory attention to GLP-1 drugs and mental health, the TRIUMPH trials include structured psychiatric safety assessments. The PHQ-9 (depression screening) and C-SSRS (Columbia-Suicide Severity Rating Scale) are standard instruments in modern obesity drug trials, particularly after the FDA's investigation highlighted the importance of systematic psychiatric monitoring.

Triple Agonism and Brain Effects

Retatrutide's unique mechanism — activating GLP-1, GIP, and glucagon receptors — means it has more pathways through which to influence brain function:

• GLP-1: Anti-inflammatory effects, BDNF upregulation, serotonin/dopamine modulation (shared with semaglutide)
• GIP: Cognitive function, synaptic plasticity, hippocampal neurogenesis (shared with tirzepatide, not available in semaglutide)
• Glucagon: Improved brain energy metabolism, potential neuroprotective effects through enhanced glucose regulation

What We Do Not Know

• No psychiatric outcome data from TRIUMPH has been published
• The interaction between three receptor agonists on brain function has not been characterized
• Whether retatrutide's pharmacokinetic profile (weekly dosing, long half-life) produces different central nervous system effects than other GLP-1 drugs
• How retatrutide affects patients with pre-existing psychiatric conditions (these patients are typically excluded from obesity trials)

Frequently Asked Questions

Sources

• U.S. Food and Drug Administration. (January 2025). FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP-1 RA Medications. Meta-analysis of 91 trials, 107,910 participants.
• Wadden, T.A., et al. (2024). Psychiatric Safety of Semaglutide for Weight Management: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials. JAMA Internal Medicine.
• Wadden, T.A., et al. (2026). Psychiatric Safety of Tirzepatide in People With Obesity: A Post Hoc Analysis of SURMOUNT. Obesity.
• Zheng, Z., et al. (2020). Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function. Frontiers in Pharmacology.
• Faivre, E., & Bhatt, D.K. (2011). Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis. PubMed.
• FAERS disproportionality analysis. Depression and suicide/self-injury signals for semaglutide, liraglutide, and tirzepatide. Journal of Affective Disorders.
• eClinicalMedicine. (2025). Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data. The Lancet.
• Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.
• ClinicalTrials.gov: Retatrutide TRIUMPH trials.

Medical Disclaimer

The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency.

Do not use this information to make decisions about your health without consulting a qualified healthcare provider. The information on this page summarizes published research on GLP-1 receptor agonists and mental health — it does not constitute psychiatric advice or guidance on medication changes.

If you or someone you know is experiencing suicidal thoughts, contact the 988 Suicide and Crisis Lifeline by calling or texting 988.

This site is not affiliated with Eli Lilly and Company or any pharmaceutical manufacturer.